Raptiva Genentech Inc. - Treatment for Psoriasis

Raptiva is the first biologic therapy that is designed to provide continuous control of chronic moderate-to-severe plaque psoriasis and can be self-administered by patients as a single, once-weekly, subcutaneous injection. Raptiva has been approved for the treatment of chronic moderate-to-severe plaque psoriasis in adults age 18 or older who are candidates for systemic therapy or phototherapy.

Posted: October 2003

View comments

Hide
(web1)